Recommended regimens listed by evidence level and alphabetically for:
Treatment-Naive Genotype 1a Patients With Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASsb for elbasvir | 12 weeks | I, A |
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) | 12 weeks | I, A |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)c | 8 weeks | I, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Includes genotype 1a RASs at amino acid position 28, 30, 31, or 93 known to confer antiviral resistance. If 1 or more RASs are present, another recommended regimen should be used. c Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. For patients with HIV/HCV coinfection, a treatment duration of 12 weeks is recommended. |
Recommended regimens listed by evidence level and alphabetically for:
Treatment-Naive Genotype 1b Patients With Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) | 12 weeks | I, A |
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) | 12 weeks | I, A |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b | 8 weeksc | I, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. c For HIV/HCV-coinfected patients, a treatment duration of 12 weeks is recommended. |
Recommended regimens listed by evidence level and alphabetically for:Treatment-Naive Genotype 2 Patients With Compensated Cirrhosisa |
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b | 8 weeksc | I, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. c For HIV/HCV-coinfected patients, a treatment duration of 12 weeks is recommended. |
Recommended and alternative regimens listed by evidence level and alphabetically for:
Treatment-Naive Genotype 3 Patients With Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b | 8 weeksc | I, B |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for patients without baseline NS5A RAS Y93H for velpatasvir | 12 weeks | I, A |
ALTERNATIVE | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) with weight-based ribavirin for patients with baseline NS5A RAS Y93H for velpatasvir | 12 weeks | IIa, A |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) for patients with baseline NS5A RAS Y93H for velpatasvir | 12 weeks | IIa, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. c For HIV/HCV-coinfected patients, a treatment duration of 12 weeks is recommended. |
Recommended regimens listed by evidence level and alphabetically for:
Treatment-Naive Genotype 4 Patients With Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b | 8 weeksc | I, B |
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) | 12 weeks | IIa, B |
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) | 12 weeks | IIa, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. c For HIV/HCV-coinfected patients, a treatment duration of 12 weeks is recommended. |
Recommended regimens listed by evidence level and alphabetically for:
Treatment-Naive Genotype 5 or 6 Patients With and Without Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b | 8 weeksc | I, Ad |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, B |
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)e | 12 weeks | IIa, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. c For HIV/HCV-coinfected patients, a treatment duration of 12 weeks is recommended. d For compensated cirrhosis, rating is I, B. e Not recommended for genotype 6e if subtype is known. |